Mazyar Shadman, MD, MPH, on Addressing Unmet Needs in Follicular Lymphoma With MB-106

“Being able to administer this product or any cellular therapy product in the outpatient setting is important on many levels. For patients, it's important not to spend days and nights in the hospital... Being able to be able to go back home is meaningful to most of the patients.”

Mustang Bio’s MB-106, aCD20-targeted chimeric antigen receptor (CAR) T-cell therapy, has demonstrated efficacy in follicular lymphoma (FL), according to updated data from a phase 1/2 trial (NCT03277729). Findings from the FL cohort were presented at the European Hematology Association (EHA) 2022 Congress, June 9-12, held both virtually and in Vienna, Austria, by Mazyar Shadman, MD, MPH, associate professor, clinical research division, Fred Hutchinson Cancer Center, where the trial was conducted.

Eighteen patients have been treated in the FL cohort. All patients, except for the first of each dose cohort, were infused in the outpatient setting. Investigators observed an overall response rate (ORR) was 94% (n = 17) and complete response (CR) rate was 78% (n = 14). Three patients (17%) had a partial response and 1 (5%) experienced disease progression. No cases of grade 3 or above cytokine release syndrome were observed and there was no neurotoxicity observed.

CGTLive spoke with Shadman to learn more about the trial and next steps. He also discussed future research with MB-106 to address unmet needs in FL.

REFERENCE

Shadman M, Yeung C, Redman M, et al. Efficacy and safety of a third generation CD20 CART (MB-106) for treatment of relapsed/refractory follicular lymphoma (FL). Presented at: EHA 2022 Congress, June 9-12, Vienna, Austria and virtually. Abstract #S207.